Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,447,926

« Back to Dashboard
Patent 5,447,926 protects BESIVANCE and is included in one NDA.

This patent has twelve patent family members in ten countries.

Summary for Patent: 5,447,926

Title: Quinolone carboxylic acid derivatives
Abstract:A quinolone carboxylic acid derivative having the following formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group, an aralkyl group, an ester residual group which can be hydrolyzed in living bodies, R.sup.2 is a hydrogen atom or an amino group which may be substituted by one or two lower alkyl groups, X is a hydrogen atom or a halogen atom, Y is CH.sub.2, O, S, SO, SO.sub.2, or N--R.sup.3, wherein R.sup.3 is a hydrogen atom or a lower alkyl group, and Z is an oxygen atom or two hydrogen atoms; or a salt thereof; and an antimicrobial agent comprising the same. The compound exhibits a superior antimicrobial activity, especially against gram positive microorganisms, and is thus useful for the treatments and prevention of various infectious diseases in clinics.
Inventor(s): Konno; Fujiko (Tomisato, JP), Shibata; Akihiro (Yachiyo, JP), Matsuda; Hideaki (Abiko, JP), Asaoka; Takemitsu (Narita, JP), Kawahara; Ryuichi (Ichikawa, JP), Taido; Naokata (Funabashi, JP), Kuraishi; Tasdayuki (Chiba, JP), Takeda; Sunao (Ichihara, JP)
Assignee: SS Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/305,977
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bausch And Lomb
besifloxacin hydrochloride
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,447,926

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2-191339Jul 19, 1990
Japan3-079774Apr 12, 1991

Non-Orange Book Patents for Patent: 5,447,926

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,385,900 Quinoline carboxylic acid derivatives<disabled in preview>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,447,926

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
Japan2613139May 21, 1997
Hong Kong125296Jul 19, 1996
JapanH054968Jan 14, 1993
JapanH08169880Jul 02, 1996
Austria128707Oct 15, 1995
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn